Business, Companies, coronavirus

The NASDAQ-listed Ocugen has rights to commercialise Covaxin in the US.

Bharat Biotech is working on a war footing to roll out its COVID-19 vaccine, Covaxin, from its Malur manufacturing site near Bengaluru, Karnataka, by the end of June, sources told Moneycontrol.

The Malur site has a capacity to manufacture about 10,000 kilolitres (KL) of Covaxin drug substance annually, and will be the biggest production site for the company, Moneycontrol learns from sources.

The site is expected to produce 30 million doses in July and 50 million by August.

Bharat Biotech experts have been frequenting between Hyderabad and Bengaluru in the last few months to help install equipment and to get production batches in place, sources said.

“The (Malur) site is capable of expanding Covaxin production by more than 5 times,” a person, who didn’t want to be named, said.

Bharat Biotech is yet to respond to questions from Moneycontrol on the existing capacity, and the timeline of the rollout from the Karnataka site.

Orders and cash

Malur site is critical as the company, flush with orders and cash, is scrambling to expand to manufacturing capacities of Covaxin. With the facility coming on board, Bharat Biotech’s internal capacity of Covaxin is expected to hit 500 million doses per annum.

To be sure, the vaccine maker received Rs 65 crore to repurpose its new Karnataka facility to increase Covaxin production capacity.

In addition, the central government has cleared a credit of Rs 1,500 crore in April to ramp up vaccine capacities. The central government has earlier placed orders for 5.5 million doses of Covaxin in January and 20 million doses in March. Later, it followed it up with an order of 50 million doses for May, June and July, by paying an advance of Rs 787.50 crore.

It recently signed another order for 190 million doses till December on payment of 30 percent advance. As per a back-of-the-envelope calculation, at the current price of Rs 150 per dose, this order would fetch Bharat Biotech about Rs 2,838 crore. Bharat Biotech will have to pay a royalty of 5 percent on net sales to ICMR.

Target of 700 million doses per year

Bharat Biotech had, in May, announced that it will add an additional 200 million doses per year of Covaxin from its Chiron Behring Vaccines subsidiary at Ankleshwar, Gujarat. The company’s plan is to hit 700 million doses per year by 2021.

Currently, the entire production of Covaxin is done from Bharat Biotech’s Genome Valley facilities on the outskirts of Hyderabad, which has a capacity to produce about 10-12 million doses per month.

The Malur facility, owned by Bharat Biotech’s sister concern Biovet, was originally meant to make animal vaccines — more specifically, Foot & Mouth Disease vaccine. The site was repurposed for manufacturing Covaxin, with multiple production lines. The facility has recently received approval from the Karnataka State Pollution Control Board to begin Covaxin production.

Bharat Biotech had earlier said that it takes around four months for manufacturing, testing and releasing a batch of Covaxin. The company noted that the entire process is complex and multifactorial and requires coordinated efforts from several agencies.


Japan travel news, japan travel guides, japan holiday destinations and japan reviews

LATEST NEWS

NEWS RELATED

Victoria's Secret hires Priyanka Chopra, six others in major rebranding effort

Priyanka Chopra (File image: Reuters/Caitlin Ochs) American lingerie giant Victoria’s Secret has signed a new roster of female brand representatives that includes Indian actor Priyanka Chopra Jonas. The brand’s previous campaigns had come under scrutiny for their embodiment of male fantasy over an accurate representation of what women seek in…

Read more: Victoria's Secret hires Priyanka Chopra, six others in major rebranding effort

1More ComfoBuds Pro earbuds review: Good audio offering in its price range

1MORE ComfoBuds Pro One of the main issues many users have with true wireless earbuds is that they are uncomfortable to wear for long hours. Unfortunately, only a handful of brands work towards providing a comfortable fit without sacrificing the audio quality or features. 1More is one of those brands,…

Read more: 1More ComfoBuds Pro earbuds review: Good audio offering in its price range

US FCC votes to launch further crackdown on Huawei, ZTE equipment

The US Federal Communications Commission (FCC) voted 4-0 Thursday to advance a plan to end installation of equipment in US telecommunications networks from Chinese companies deemed national security threats like Huawei and ZTE and to halt equipment authorizations for applications from those companies. Under the proposed rules that won initial…

Read more: US FCC votes to launch further crackdown on Huawei, ZTE equipment

Facebook launches ads globally for Instagram Reels

Facebook Inc is launching ads globally on its TikTok clone Instagram Reels, the company said on Thursday. The social media company, which is aiming to make money from its short-form video feature, began testing Instagram Reels ads in India, Brazil, Germany and Australia in April. The tests ran with brands…

Read more: Facebook launches ads globally for Instagram Reels

Fortis says only 1% of its workforce who received two COVID-19 jabs required ICU/ventilator support

Fortis Healthcare  | In the September quarter, Rakesh Junjhunwala held a 2.65 percent holding in the stock, and FIIs have increased its stake to 41.04 percent from 40.98 percent in the June quarter. In FY21 so far the stock price has risen 0 percent to Rs 125.70 as on October 26. Fortis Healthcare, one of India’s largest private hospital chain on…

Read more: Fortis says only 1% of its workforce who received two COVID-19 jabs required ICU/ventilator support

RDIF says Sputnik V will soon offer booster shot that's adjusted to work against Delta variant

Representative image of the Russian Sputnik V COVID-19 vaccine Russian sovereign fund RDIF on June 17 said its COVID-19 vaccine Sputnik V will soon offer a booster shot, adjusted to work against the Delta variant of coronavirus, to other vaccine manufacturers. Sputnik V uses heterogeneous boosting with two shots by…

Read more: RDIF says Sputnik V will soon offer booster shot that's adjusted to work against Delta variant

Widening Covishield gap - did the govt rely on proper evidence and follow due process?

Image: AP The government’s decision to increase the gap between two doses of the Covishield vaccine to 12-16 weeks was taken unanimously, an official statement said after media reports alleged dissent by some members of a technical panel. According to media reports, at least three members of the Standing Technical…

Read more: Widening Covishield gap - did the govt rely on proper evidence and follow due process?

More than half of new Mercedes-Benz S-Class, costing Rs 2.17 crore, sold even before launch

Mercedes-Benz S-Klasse, 2020, Outdoor, Fahraufnahme, Exterieur: Hightechsilber Mercedes-Benz S-Class, 2020, outdoor, driving shot, exterior: hightech silver More than 75 units of the fully imported Mercedes-Benz S-Class have been sold even before its official launch on June 17. The Pune-based luxury car maker has priced its flagship limousine at Rs 2.17…

Read more: More than half of new Mercedes-Benz S-Class, costing Rs 2.17 crore, sold even before launch

Federal Bank board approves Rs 916 crore fund raise from IFC

Wipro IT Services to issue $750 million dollar denominated notes on June 23

Unlock India: Malls, theatres, hotels open up, albeit with air of caution

COVID-19 impact | Indian Hotels MD salary down by 50% in FY21, others follow

COVID-19 impact: Kotak Life Insurance to incur upto Rs 275 crore loss in shareholders account in Q1

BMC orders inquiry into alleged fake vaccination drive at Mumbai's residential society

In final leg of Sputnik V pilot rollout, will announce commercial launch soon, says Dr Reddy's

Google Pay launches cards tokenisation with SBI, other banks in collaboration with Visa

OTHER NEWS